跳转至内容
Merck
CN

SML0123

Deflazacort

≥98% (HPLC)

别名:

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C25H31NO6
化学文摘社编号:
14484-47-0
分子量:
441.52
NACRES:
NA.77
PubChem Substance ID:
329825173
UNSPSC Code:
51111800
EC Number:
238-483-7
MDL number:
MFCD00866106

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

FBHSPRKOSMHSIF-GRMWVWQJSA-N

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

SMILES string

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Deflazacort is an Anti-inflammatory glucocorticoid
Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000479246
0000375408
0000366529
0000375408
0000366529

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Corrado Angelini et al.
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 31(1), 9-15 (2012-06-05)
Steroids have been used since two decades and several trials were conducted to establish their efficacy in DMD patients with various regimens. The clinical outcomes showed increased function in the treated boys, and in a single trial with deflazacort, prolongation
Elena Stacy Mazzone et al.
PloS one, 8(1), e52512-e52512 (2013-01-18)
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to
Meilan M Rutter et al.
Neuromuscular disorders : NMD, 22(12), 1046-1056 (2012-09-13)
This study evaluated efficacy and safety of growth hormone treatment in Duchenne muscular dystrophy boys with glucocorticoid-induced growth failure. We reviewed 39 consecutive boys (average age 11.5 years; 32 ambulatory) treated with growth hormone for 1 year during a four-year
Elaine C da Silva et al.
Arquivos de neuro-psiquiatria, 70(3), 191-195 (2012-03-07)
To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). Thirty-three patients with DMD
David E Lebel et al.
The Journal of bone and joint surgery. American volume, 95(12), 1057-1061 (2013-06-21)
Duchenne muscular dystrophy, a progressive muscle disorder that occurs in males, causes a gradual decline in muscle strength. This progressive decline is associated with the development of scoliosis. Previous studies have shown that the use of glucocorticoids slows the progression
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持